SULFAMETHOXAZOLE AND TRIMETHOPRIM by Fosun Pharma is clinical pharmacology sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. First approved in 1982.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
Sulfamethoxazole and trimethoprim (SMX-TMP) is a fixed-dose combination antibiotic that synergistically inhibits bacterial folate synthesis, making it a broad-spectrum agent effective against gram-positive and gram-negative bacteria. It is used to treat urinary tract infections, Pneumocystis jirovecii pneumonia (PCP), and other serious infections across both immunocompromised and immunocompetent populations. The mechanism relies on sequential blockade of dihydrofolate reductase and dihydropteroate synthase, providing bactericidal activity.
Product is in late-stage lifecycle with minimal current job openings, indicating a mature/declining team and cost-management focus rather than growth investment.
CLINICAL PHARMACOLOGY Sulfamethoxazole and trimethoprim is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole is metabolized…
Worked on SULFAMETHOXAZOLE AND TRIMETHOPRIM at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SMX-TMP offers limited career growth opportunities due to the product's mature, genericized status and approaching loss of exclusivity. Roles on this asset typically focus on cost optimization, market access, and niche indication management rather than brand-building or innovation, making it less attractive for career advancement.